13 Mar, EOD - Indian

Nifty IT 36122.5 (-0.52)

Nifty Smallcap 100 14897.35 (-0.98)

Nifty Pharma 20386.85 (-0.18)

Nifty Midcap 100 48125.1 (-0.75)

Nifty 50 22397.2 (-0.33)

Nifty Bank 48060.4 (0.01)

Nifty Next 50 58976.1 (-0.51)

SENSEX 73828.91 (-0.27)

13 Mar, EOD - Global

NIKKEI 225 37053.1 (0.72)

HANG SENG 23959.98 (2.12)

S&P 5640.75 (1.83)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(10 Jan 2025, 14:45)

Shilpa Medicare gets European authority nod for Tadalafil drug

Shilpa Medicare informed that it has received marketing authorization from Portugal, Europe, for Tadalafil Orodispersible Films, 20 mg.


The approved drug is indicated for the treatment of erectile dysfunction (sometimes called impotence) in adult males. The total Europe market for oral Tadalafil formulations is estimated at about $400 million.

The drug maker stated that it becomes the first company in the world to receive approval for this product as a convenient, patient friendly oral mouth dissolving/dispersing film formulation. This approval is a hybrid application and Shilpa’s product is bioequivalent to the reference product.

The approval has been granted for the company's finished dosage form manufacturing facility, Unit VI, located in Dabaspet, Bengaluru, Karnataka. Currently approved by the MHRA UK, this marks the second approval for a prescription oral mouth-dissolving film product in the European/UK regulated markets from this facility. It is involved in the manufacturing, packaging, labeling, and testing of finished dosage forms, including oral dispersible/dissolving films and transdermal patches.

Raichur-based Shilpa Medicare is a vertically integrated manufacturer and distributor of quality drugs to global markets, specializing in the oncology therapeutic segment and introducing novel drugs focusing on patient convenience and compliance.

The company’s consolidated net profit soared to Rs 17.94 crore in Q2 FY25 as against Rs 1.61 crore posted in Q2 FY24. Revenue from operations rose 9.8% to Rs 343.80 crore in the quarter ended 30 September 2024.

The scrip tumbled 3.85% to currently trade at Rs 778.35 on the BSE.

More News

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

The power of the database is harnessed by our fired-up reporters to generate interesting ideas. The reader-friendly presentation of the idea, supplemented by relevant data and information, can be accessed online through Capita Telefolio and Telefolio Gold. These ideas are used by individual investors as well as institutional investors to do further research and stay ahead.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +